Literature DB >> 15149825

A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins.

F Piccioli1, S Sabatini, L Messori, P Orioli, Ch G Hartinger, B K Keppler.   

Abstract

Formation of adducts between the antitumor ruthenium(III) complex [HInd]trans-[RuCl(4)(Ind)(2)] (KP1019) and the plasma proteins serum albumin and serum transferrin was investigated by UV-vis spectroscopy, for metal-to-protein ratios ranging from 1:1 to 5:1. In both cases, formation of tight metal-protein conjugates was observed. Similar spectroscopic features were observed for both albumin and transferrin derivatives implying a similar binding mode of the ruthenium species to these proteins. Surface histidines are the probable anchoring sites for the bound ruthenium(III) ions in line with previous crystallographic results. In order to assess the stability of the KP1019-protein adducts the influence of pH, reducing agents and chelators was analysed by UV-vis spectroscopy. Notably, there was no effect of addition of EDTA on the UV-vis spectra of the conjugates. The pH-stability was high in the pH range 5-8. Experiments with sodium ascorbate showed that there was just some alteration of selected bands. The implications of the present results are discussed in relation to the pharmacological behavior of this novel class of antitumor compounds.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15149825     DOI: 10.1016/j.jinorgbio.2004.04.002

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  11 in total

1.  Insights into the binding sites of organometallic ruthenium anticancer compounds on peptides using ultra-high resolution mass spectrometry.

Authors:  Rebecca H Wills; Abraha Habtemariam; Andrea F Lopez-Clavijo; Mark P Barrow; Peter J Sadler; Peter B O'Connor
Journal:  J Am Soc Mass Spectrom       Date:  2014-02-01       Impact factor: 3.109

2.  The interactions of the ruthenium(II)-cymene complexes with lysozyme and cytochrome c.

Authors:  Dragana Stanic-Vucinic; Stefan Nikolic; Katarina Vlajic; Mirjana Radomirovic; Jelena Mihailovic; Tanja Cirkovic Velickovic; Sanja Grguric-Sipka
Journal:  J Biol Inorg Chem       Date:  2020-02-04       Impact factor: 3.358

3.  Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity.

Authors:  Maria G Mendoza-Ferri; Christian G Hartinger; Marco A Mendoza; Michael Groessl; Alexander E Egger; Rene E Eichinger; John B Mangrum; Nicholas P Farrell; Magdalena Maruszak; Patrick J Bednarski; Franz Klein; Michael A Jakupec; Alexey A Nazarov; Kay Severin; Bernhard K Keppler
Journal:  J Med Chem       Date:  2009-02-26       Impact factor: 7.446

4.  Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR.

Authors:  Naniye Cetinbas; Michael I Webb; Joshua A Dubland; Charles J Walsby
Journal:  J Biol Inorg Chem       Date:  2009-08-26       Impact factor: 3.358

5.  The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways.

Authors:  Soumya Chatterjee; Subhadip Kundu; Arindam Bhattacharyya; Christian G Hartinger; Paul J Dyson
Journal:  J Biol Inorg Chem       Date:  2008-07-03       Impact factor: 3.358

Review 6.  Anticancer activity of metal complexes: involvement of redox processes.

Authors:  Ute Jungwirth; Christian R Kowol; Bernhard K Keppler; Christian G Hartinger; Walter Berger; Petra Heffeter
Journal:  Antioxid Redox Signal       Date:  2011-05-11       Impact factor: 8.401

7.  Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019.

Authors:  Caroline Bartel; Alexander E Egger; Michael A Jakupec; Petra Heffeter; Markus Galanski; Walter Berger; Bernhard K Keppler
Journal:  J Biol Inorg Chem       Date:  2011-06-26       Impact factor: 3.862

8.  An iridium(iii)-based irreversible protein-protein interaction inhibitor of BRD4 as a potent anticancer agent.

Authors:  Hai-Jing Zhong; Lihua Lu; Ka-Ho Leung; Catherine C L Wong; Chao Peng; Siu-Cheong Yan; Dik-Lung Ma; Zongwei Cai; Hui-Min David Wang; Chung-Hang Leung
Journal:  Chem Sci       Date:  2015-07-30       Impact factor: 9.825

9.  Altered DNA binding and amplification of human breast cancer suppressor gene BRCA1 induced by a novel antitumor compound, [Ru(η(6)-p-phenylethacrynate)Cl(2)(pta)].

Authors:  Korawan Chakree; Chitchamai Ovatlarnporn; Paul J Dyson; Adisorn Ratanaphan
Journal:  Int J Mol Sci       Date:  2012-10-15       Impact factor: 5.923

10.  Alkyne Functionalization of a Photoactivated Ruthenium Polypyridyl Complex for Click-Enabled Serum Albumin Interaction Studies.

Authors:  Anja Busemann; Can Araman; Ingrid Flaspohler; Alessandro Pratesi; Xue-Quan Zhou; Vincent H S van Rixel; Maxime A Siegler; Luigi Messori; Sander I van Kasteren; Sylvestre Bonnet
Journal:  Inorg Chem       Date:  2020-05-12       Impact factor: 5.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.